MHC-mismatched mice liver transplantation promotes tumor growth in liver graft

Cancer Letters

Volumn 351, Issue 1, 2014, Pages 162-171

  Yan, Sheng ^a   Ding, Yuan ^a   Tian, Yang ^a   Lu, Zhongjie ^a   Wang, Yan ^a   Zhang, Qiyi ^a   Ye, Yufu ^a   Zhou, Lin ^a   Xie, Haiyang ^a   Chen, Hui ^a   Zheng, Minghao ^a,b   Zheng, Shusen ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Allogeneic; Graft; Immune environment; Liver transplantation; Mouse

Indexed keywords

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; EFFECTOR CELL; GROWTH RATE; IMMUNE RESPONSE; LIVER TRANSPLANTATION; LYMPHOCYTE FUNCTION; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR PROMOTION;

MUS; MUS MUSCULUS;

ALLOGENEIC; GRAFT; IMMUNE-ENVIRONMENT; LIVER TRANSPLANTATION; MOUSE;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; HISTOCOMPATIBILITY; IMMUNOLOGIC FACTORS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; LIVER TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY;

EID: 84903716217     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.05.010     Document Type: Article

References (35)

1. Williams R. Global challenges in liver disease. Hepatology 2006, 44:521-526.
2. Hertl M., Cosimi A.B. Liver transplantation for malignancy. Oncologist 2005, 10:269-281.
3. Delco F., Mullhaupt B. Should we screen for colorectal cancer in liver transplantation?. J. Hepatol. 2006, 44:32-38.
4. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004, 127:S268-S276.
5. Schlitt H.J., Neipp M., Weimann A., Oldhafer K.J., Schmoll E., Boeker K., Nashan B., Kubicka S., Maschek H., Tusch G., Raab R., Ringe B., Manns M.P., Pichlmayr R. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J. Clin. Oncol.: Official J. Am. Soc. Clin. Oncol. 1999, 17:324-331.
6. Vallejo G.H., Romero C.J., de Vicente J.C. Incidence and risk factors for cancer after liver transplantation. Crit. Rev. Oncol./Hematol. 2005, 56:87-99.
7. Buell J.F., Gross T.G., Woodle E.S. Malignancy after transplantation. Transplantation 2005, 80:S254-264.
8. Sanchez-Fueyo A., Strom T.B. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 2011, 140:51-64.
9. Starzl T.E., Lakkis F.G. The unfinished legacy of liver transplantation: emphasis on immunology. Hepatology 2006, 43:S151-S163.
10. Li W., Carper K., Perkins J.D. Enhancement of NKT cells and increase in regulatory T cells results in improved allograft survival. J. Surgical Res. 2006, 134:10-21.
11. Strauss L., Bergmann C., Whiteside T.L. Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J. Immunol. 2009, 182:1469-1480.
12. Terme M., Chaput N., Combadiere B., Ma A., Ohteki T., Zitvogel L. Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. J. Immunol. 2008, 180:4679-4686.
13. Qian S., Fung J.J., Sun H., Demetris A.J., Starzl T.E. Transplantation unresponsiveness induced by liver allografts in mouse strains with various histocompatibility disparities. Transpl. Proc. 1992, 24:1605-1606.
14. Qian S.G., Fung J.J., Demetris A.V., Ildstad S.T., Starzl T.E. Orthotopic liver transplantation in the mouse. Transplantation 1991, 52:562-564.
15. Liu Z., Fan H., Jiang S. CD4(+) T-cell subsets in transplantation. Immunol. Rev. 2013, 252:183-191.
16. Hongo D., Tang X., Dutt S., Nador R.G., Strober S. Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants. Blood 2012, 119:1581-1589.
17. Hathaway M., Burnett D., Elias E., Adams D.H. Secretion of soluble chemotactic factors, including interleukin-6: a mechanism for the recruitment of CD8-positive T lymphocytes to human liver allografts during rejection. Hepatology 1993, 18:511-518.
18. Zelenika D., Adams E., Humm S., Lin C.Y., Waldmann H., Cobbold S.P. The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance. Immunol. Rev. 2001, 182:164-179.
19. Brown R., Emond J.C. Managing access to liver transplantation: implications for gastroenterology practice. Gastroenterology 2007, 132:1152-1163.
20. Donia M., Mangano K., Amoroso A., Mazzarino M.C., Imbesi R., Castrogiovanni P., Coco M., Meroni P., Nicoletti F. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. J. Autoimmun. 2009, 33:135-140.
21. Demirkiran A., Kok A., Kwekkeboom J., Kusters J.G., Metselaar H.J., Tilanus H.W., van der Laan L.J. Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transplantation: Official Publ. Am. Assoc. Study Liver Diseases Int. Liver Transplantation Soc. 2006, 12:277-284.
22. Qian S., Lu L., Li Y., Fu F., Li W., Starzl T.E., Thomson A.W., Fung J.J. Apoptosis of graft-infiltrating cytotoxic T cells: a mechanism underlying "split tolerance" in mouse liver transplantation. Transpl. Proc. 1997, 29:1168-1169.
23. Sugioka A., Morita M., Esaki T., Soga R., Hasumi A. Course and mechanism of tolerance induction after mouse liver transplantation. Transpl. Proc. 1999, 31:459.
24. Thai N.L., Qian S., Fu F., Li Y., Sun H., Demetris A.J., Duquesnoy R.J., Starzl T.E., Fung J.J. Mouse liver transplantation tolerance: the role of hepatocytes and nonparenchymal cells. Transpl. Proc. 1995, 27:509-510.
25. Parasuraman R.K., Venkat K.K., Abouljoud M., Samarapungavan D., Rocher L., Koffron A.J. Renal allograft outcome in recipients of positive-crossmatch combined liver-kidney transplantation. Transpl. Proc. 2013, 45:3269-3272.
26. Larmonier N., Marron M., Zeng Y., Cantrell J., Romanoski A., Sepassi M., Thompson S., Chen X., Andreansky S., Katsanis E. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol., Immunotherapy: CII 2007, 56:48-59.
27. Saul A.N., Oberyszyn T.M., Daugherty C., Kusewitt D., Jones S., Jewell S., Malarkey W.B., Lehman A., Lemeshow S., Dhabhar F.S. Chronic stress and susceptibility to skin cancer. J. Natl Cancer Inst. 2005, 97:1760-1767.
28. Castellani M.L., Anogeianaki A., Felaco P., Toniato E., De Lutiis M.A., Shaik B., Fulcheri M., Vecchiet J., Tete S., Salini V., Theoharides T.C., Caraffa A., Antinolfi P., Frydas I., Conti P., Cuccurullo C., Ciampoli C., Cerulli G., Kempuraj D. IL-35, an anti-inflammatory cytokine which expands CD4+CD25+ Treg Cells. J. Biol. Regul. Homeost. Agents 2010, 24:131-135.
29. Taylor M.D., Harris A., Babayan S.A., Bain O., Culshaw A., Allen J.E., Maizels R.M. CTLA-4 and CD4+ CD25+ regulatory T cells inhibit protective immunity to filarial parasites in vivo. J. Immunol. 2007, 179:4626-4634.
30. Bardel E., Larousserie F., Charlot-Rabiega P., Coulomb-L'Hermine A., Devergne O. Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J. Immunol. 2008, 181:6898-6905.
31. Collison L.W., Chaturvedi V., Henderson A.L., Giacomin P.R., Guy C., Bankoti J., Finkelstein D., Forbes K., Workman C.J., Brown S.A., Rehg J.E., Jones M.L., Ni H.T., Artis D., Turk M.J., Vignali D.A. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 2010, 11:1093-1101.
32. Laurence A., Amarnath S., Mariotti J., Kim Y.C., Foley J., Eckhaus M., O'Shea J.J., Fowler D.H. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity 2012, 37:209-222.
33. Bhoori S., Toffanin S., Sposito C., Germini A., Pellegrinelli A., Lampis A., Mazzaferro V. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J. Hepatol. 2010, 52:771-775.
34. Te H.S., Dasgupta K.A., Cao D., Satoskar R., Mohanty S.R., Reau N., Millis J.M., Jensen D.M. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin. Transplant. 2012, 26:826-832.
35. Waidmann O., Hofmann W.P., Zeuzem S., Trojan J. mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. J. Hepatol. 2011, 54:396-398.